<?xml version="1.0" encoding="UTF-8"?>
<ref id="B42-vaccines-07-00199">
 <label>42.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Gidding</surname>
    <given-names>H.F.</given-names>
   </name>
   <name>
    <surname>Quinn</surname>
    <given-names>H.E.</given-names>
   </name>
   <name>
    <surname>Hueston</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Dwyer</surname>
    <given-names>D.E.</given-names>
   </name>
   <name>
    <surname>McIntyre</surname>
    <given-names>P.B.</given-names>
   </name>
  </person-group>
  <article-title>Declining measles antibodies in the era of elimination: Australiaâ€™s experience</article-title>
  <source>Vaccine</source>
  <year>2018</year>
  <volume>36</volume>
  <fpage>507</fpage>
  <lpage>513</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.12.002</pub-id>
  <?supplied-pmid 29269156?>
  <pub-id pub-id-type="pmid">29269156</pub-id>
 </element-citation>
</ref>
